[go: up one dir, main page]

KR970706816A - 알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease) - Google Patents

알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)

Info

Publication number
KR970706816A
KR970706816A KR1019970702700A KR19970702700A KR970706816A KR 970706816 A KR970706816 A KR 970706816A KR 1019970702700 A KR1019970702700 A KR 1019970702700A KR 19970702700 A KR19970702700 A KR 19970702700A KR 970706816 A KR970706816 A KR 970706816A
Authority
KR
South Korea
Prior art keywords
alpha
disease
alzheimer
acetonitrile
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970702700A
Other languages
English (en)
Other versions
KR100393365B1 (ko
Inventor
로저 에드워드 마크웰
쥴리에 호킨스
캐롤 웬디 그레이
Original Assignee
데이비드 로버츠
스미스클라인 비참 피. 엘. 씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 로버츠, 스미스클라인 비참 피. 엘. 씨. filed Critical 데이비드 로버츠
Publication of KR970706816A publication Critical patent/KR970706816A/ko
Application granted granted Critical
Publication of KR100393365B1 publication Critical patent/KR100393365B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

알츠하이머 질환을 앓고 있는, 또한 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질의 프로세싱을 촉진하는 방법, 및 효과적이고, 비독성인 양의 아세토니트릴 화합물을 알츠하이머 질환을 앓고 있는, 또는 발생할 위험이 있는 환자에게 투여하여 βA4 생성을 감소시킴으로써 알츠하이머 질환의 예방 또는 치료 방법, 그리고 방법에 사용되는 의약의 제조에서의 그 화합물의 용도 및 그 방법에 사용되는 조성물.

Description

알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alapha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2, 2, 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 알츠하이머 질환을 앓고 있는 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위한 의약의 제조에 있어서의 〔R-(Z)〕-알파-(메톡시아미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염의 용도.
  2. βA4 생성을 감소시킴으로써 알츠하이머 질환의 치료 또는 예방에 사용되는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염의 용도.
  3. 비독성 유효량의 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염을 투여하는 것을 포함하는, 알츠하이머 질환을 앓고 있는, 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위한 방법.
  4. 비독성 유효량의 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염을 투여하는 것을 포함하는, 알츠하이머 질환을 잃고 있는 또는 발생할 위험이 있는 환자에게서 βA4 생성을 감소시킴으로써 알츠하이머 질환을 치료 또는 예방하는 방법.
  5. 알츠하이머 질환을 앓고 있는 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위하여 사용되는, 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염 및 제약상 허용되는 담체를 포함하는 제약 조성물.
  6. βA4 생성을 감소시킴으로써 알츠하이머 질환의 치료 및(또는) 예방에 사용되는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염 및 제약상 허용되는 담체를 포함하는 제약 조성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 제약상 허용되는 염이 모노히드로클로라이드인 용도, 방법 또는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702700A 1994-10-25 1995-10-17 알츠하이머질환에서의아밀로이드베타a4형성을감소시키는[r-(z)]-알파-(메톡시이미노)-알파-(1-아자비시클로-[2.2.2]옥트-3-일)아세토니트릴의용도 Expired - Fee Related KR100393365B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
GB9421472.3 1994-10-25

Publications (2)

Publication Number Publication Date
KR970706816A true KR970706816A (ko) 1997-12-01
KR100393365B1 KR100393365B1 (ko) 2003-12-18

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702700A Expired - Fee Related KR100393365B1 (ko) 1994-10-25 1995-10-17 알츠하이머질환에서의아밀로이드베타a4형성을감소시키는[r-(z)]-알파-(메톡시이미노)-알파-(1-아자비시클로-[2.2.2]옥트-3-일)아세토니트릴의용도

Country Status (21)

Country Link
US (1) US5891887A (ko)
EP (1) EP0786998B1 (ko)
JP (1) JPH10509697A (ko)
KR (1) KR100393365B1 (ko)
CN (1) CN1085529C (ko)
AT (1) ATE214926T1 (ko)
AU (1) AU698695B2 (ko)
BG (1) BG101500A (ko)
BR (1) BR9509433A (ko)
CZ (1) CZ287370B6 (ko)
DE (1) DE69526102T2 (ko)
DK (1) DK0786998T3 (ko)
ES (1) ES2173977T3 (ko)
GB (1) GB9421472D0 (ko)
HU (1) HUT77007A (ko)
NO (1) NO312055B1 (ko)
NZ (1) NZ295155A (ko)
PT (1) PT786998E (ko)
SK (1) SK50497A3 (ko)
WO (1) WO1996012486A1 (ko)
ZA (1) ZA958946B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
KR20010034588A (ko) * 1998-03-11 2001-04-25 피터 기딩스 조성물
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034146T2 (de) * 1989-04-13 2005-07-14 Beecham Group P.L.C., Brentford Chemische Verbindungen
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
NZ295155A (en) 2000-07-28
DE69526102T2 (de) 2002-10-31
PT786998E (pt) 2002-09-30
CN1085529C (zh) 2002-05-29
EP0786998A1 (en) 1997-08-06
CZ125197A3 (en) 1997-07-16
GB9421472D0 (en) 1994-12-07
CZ287370B6 (en) 2000-11-15
HUT77007A (hu) 1998-03-02
NO971899L (no) 1997-04-24
ZA958946B (en) 1996-08-20
AU698695B2 (en) 1998-11-05
HK1002057A1 (en) 1998-07-31
MX9703077A (es) 1997-07-31
SK50497A3 (en) 1997-09-10
KR100393365B1 (ko) 2003-12-18
BG101500A (en) 1998-01-30
JPH10509697A (ja) 1998-09-22
ES2173977T3 (es) 2002-11-01
BR9509433A (pt) 1997-09-16
NO971899D0 (no) 1997-04-24
DE69526102D1 (de) 2002-05-02
EP0786998B1 (en) 2002-03-27
US5891887A (en) 1999-04-06
ATE214926T1 (de) 2002-04-15
DK0786998T3 (da) 2002-07-15
NO312055B1 (no) 2002-03-11
WO1996012486A1 (en) 1996-05-02
AU3843195A (en) 1996-05-15
CN1170365A (zh) 1998-01-14

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0110420A (pt) Agonistas muscarìnicos
GR3022459T3 (en) Quinuclidine derivative as substance p antagonist.
CA2427227A1 (en) Lactam compound
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
BG105302A (en) Means for improving cognition
KR970061244A (ko) 치매 치료용 약학 조성물
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
KR970706816A (ko) 알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
KR890003378A (ko) 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물
BR0009080A (pt) Método de tratamento da apnéia do sono
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
WO2004014391B1 (en) Use of carboxamides for the treatment of tinnitus
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060722

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060722

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301